Rachel Thijssen

2.9k citations

29 papers · 932 indexed · 1 hit paper · h-index 15

Co-authors: David C.S. Huang Andrew W. Roberts Mary Ann Anderson Eric Eldering Piers Blombery Peter E. Czabotar Richard W. Birkinshaw Ian J. Majewski
Topics: Chronic Lymphocytic Leukemia Research (25 papers)PI3K/AKT/mTOR signaling in cancer (7 papers)Cell death mechanisms and regulation (5 papers)
Cited by: Genetics Hematology Pathology and Forensic Medicine
Journals: Nucleic Acids Research Nature Communications Blood
Partner nations: Australia Netherlands France

In The Last Decade

Rachel Thijssen

29 papers receiving 921 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Rachel Thijssen

Since Specialization

Citations

This map shows the geographic impact of Rachel Thijssen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Thijssen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Thijssen more than expected).

Fields of papers citing papers by Rachel Thijssen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Thijssen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Thijssen. The network helps show where Rachel Thijssen may publish in the future.

Co-authorship network of co-authors of Rachel Thijssen

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Thijssen. A scholar is included among the top collaborators of Rachel Thijssen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Thijssen. Rachel Thijssen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single-cell Rapid Capture Hybridization sequencing reliably detects isoform usage and coding mutations in targeted genes 2025 ·Genome Research ·Hongke Peng,Jafar S. Jabbari,Luyi Tian,(unknown),(unknown),Chong Chyn Chua,Natasha S. Anstee,(unknown),Andrew H. Wei,N. Davidson,Andrew W. Roberts,David C.S. Huang,Matthew E. Ritchie,Rachel Thijssen	1
2	Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications 2024 ·British Journal of Haematology ·Mingyuan Gao,Angela Georgiou,Victor S. Lin,(unknown),Christine White,Mary Ann Anderson,Matthew P. McCormack,Andrew W. Roberts,David C.S. Huang,Rachel Thijssen	1
3	RUV-III-NB: normalization of single cell RNA-seq data 2022 ·Nucleic Acids Research ·Agus Salim,Ramyar Molania,Jianan Wang,Alysha De Livera,Rachel Thijssen,Terence P. Speed	7
4	JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL 2022 ·Molecular Oncology ·(unknown),Rachel Thijssen,(unknown),(unknown),(unknown),Simon P. Mackay,Julie Dubois,Clemens Mellink,Arnon P. Kater,Eric Eldering	15
5	Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors 2021 ·Blood Advances ·Ella R. Thompson,Tamia Nguyen,(unknown),John Markham,Mary Ann Anderson,Sasanka M. Handunnetti,Rachel Thijssen,Paul Yeh,Constantine S. Tam,John F. Seymour,Andrew W. Roberts,David Westerman,Piers Blombery	17
6	Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL 2021 ·Cell Death and Differentiation ·(unknown),Rachel Thijssen,Christopher M. West,Louise Young,Roel van Kampen,Elaine Willmore,Simon P. Mackay,Arnon P. Kater,Eric Eldering	66
7	BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic 2020 ·Cancers ·Victor S. Lin,(unknown),David C.S. Huang,Rachel Thijssen	15
8	Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells 2020 ·Cell Death and Differentiation ·Rachel Thijssen,Silvia Álvarez-Díaz,(unknown),Mingyuan Gao,David Segal,Zhen Xu,Andreas Strasser,David C.S. Huang	8
9	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations 2019 ·Nature Communications ·Richard W. Birkinshaw,Jianan Gong,Cindy S. Luo,Daisy Lio,Christine White,Mary Ann Anderson,Piers Blombery,Guillaume Lessène,Ian J. Majewski,Rachel Thijssen,Andrew W. Roberts,David C.S. Huang,Peter M. Colman,Peter E. Czabotar	172
10	Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma 2019 ·Oncogene ·Michael A. Dengler,Charis E. Teh,Rachel Thijssen,Lahiru Gangoda,Ping Lan,Marco J. Herold,Daniel H.D. Gray,Gemma L. Kelly,Andrew W. Roberts,Jerry M. Adams	18
11	Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax 2019 ·Blood ·Piers Blombery,Ella R. Thompson,Tamia Nguyen,Xiangting Chen,Michelle McBean,Richard W. Birkinshaw,Peter E. Czabotar,Rachel Thijssen,Mary Ann Anderson,John F. Seymour,David Westerman,David C.S. Huang,Andrew W. Roberts	3
12	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemiabreakdown → 2018 ·Cancer Discovery ·Piers Blombery,Mary Ann Anderson,Jianan Gong,Rachel Thijssen,Richard W. Birkinshaw,Ella R. Thompson,Charis E. Teh,Tamia Nguyen,Zhen Xu,Christoffer Flensburg,Thomas E. Lew,Ian J. Majewski,Daniel H.D. Gray,David Westerman,Constantine S. Tam,John F. Seymour,Peter E. Czabotar,David C.S. Huang,Andrew W. Roberts	276
13	Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition 2017 ·Leukemia ·(unknown),Rachel Thijssen,Arnon P. Kater,Eric Eldering	20
14	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia 2016 ·Blood ·Rachel Thijssen,(unknown),(unknown),(unknown),Jennifer R. Brown,Stacey M. Fernandes,(unknown),Jean‐Marie Michot,Michael Hallek,Barbara Eichhorst,Hans Christian Reinhardt,Johanna C. Bendell,Ingrid A. M. Derks,Roel J.W. van Kampen,Kristen Hege,Marie José Kersten,Torsten Trowe,Ellen Filvaroff,Eric Eldering,Arnon P. Kater	59
15	The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells 2015 ·Leukemia ·Rachel Thijssen,(unknown),(unknown),Martin F. M. de Rooij,Annemieke Kuil,(unknown),Taco W. Kuijpers,Joke W. Baars,Angéla Virone-Oddos,Marcel Spaargaren,Coumaran Égile,Marinus H. J. van Oers,Eric Eldering,Marie José Kersten,Arnon P. Kater	20
16	Targeting BCR-Independent Proliferation of CLL Cells 2015 ·Blood ·(unknown),Arnon P. Kater,Rachel Thijssen,Eric Eldering	1
17	Ecodriving acceptance: An experimental study on anticipation behavior of truck drivers 2014 ·Transportation Research Part F Traffic Psychology and Behaviour ·Rachel Thijssen,Théo Hofman,Jaap Ham	34
18	Combined Inhibition of Phosphatidylinositol 3-Kinase (PI3K) Isoform α and δ By the Pan-Class I PI3K Inhibitor SAR245409 (XL765) in Primary Chronic Lymphocytic Leukemia Cells Blocks Survival, Adhesion and Proliferation 2014 ·Blood ·Rachel Thijssen,(unknown),(unknown),(unknown),Marcel Spaargaren,Coumaran Égile,Marie José Kersten,Eric Eldering,Arnon P. Kater	1
19	CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex 2013 ·Cell Death and Disease ·Chiel Maas,(unknown),(unknown),Rachel Thijssen,(unknown),Anna Malara,Anja Krippner‐Heidenreich,John Silke,(unknown),Eric Eldering	27
20	Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models Of CLL – The Role Of Abl and Btk 2013 ·Blood ·Rachel Thijssen,Christian R. Geest,(unknown),(unknown),Bogdan I. Florea,(unknown),Herman S. Overkleeft,Marinus H. J. van Oers,Marcel Spaargaren,Arnon P. Kater,Eric Eldering	6

About Rachel Thijssen

Rachel Thijssen is a scholar working on Genetics, Immunology and Toxicology, having authored 29 papers that have together received 932 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (25 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Cell death mechanisms and regulation (5 papers). The work is most often cited by research in Genetics (457 citations), Hematology (196 citations) and Pathology and Forensic Medicine (271 citations). Rachel Thijssen has collaborated with scholars based in Australia, Netherlands and France. Frequent co-authors include David C.S. Huang, Andrew W. Roberts, Mary Ann Anderson, Eric Eldering, Piers Blombery, Peter E. Czabotar, Richard W. Birkinshaw, Ian J. Majewski, Arnon P. Kater and Jianan Gong. Their work appears in journals such as Nucleic Acids Research, Nature Communications and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact